Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 8 studies | 27% ± 9% | |
astrocyte | 7 studies | 40% ± 18% | |
endothelial cell | 6 studies | 21% ± 5% | |
microglial cell | 5 studies | 20% ± 5% | |
GABAergic neuron | 5 studies | 42% ± 19% | |
oligodendrocyte precursor cell | 5 studies | 30% ± 10% | |
glutamatergic neuron | 4 studies | 53% ± 19% | |
interneuron | 4 studies | 40% ± 20% | |
epithelial cell | 3 studies | 25% ± 10% | |
macrophage | 3 studies | 21% ± 4% | |
transit amplifying cell | 3 studies | 31% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 795.11 | 1445 / 1445 | 100% | 16.42 | 183 / 183 |
brain | 100% | 764.63 | 2638 / 2642 | 100% | 22.43 | 705 / 705 |
intestine | 100% | 690.45 | 966 / 966 | 99% | 15.04 | 524 / 527 |
breast | 100% | 899.78 | 459 / 459 | 99% | 12.80 | 1105 / 1118 |
lung | 99% | 590.22 | 571 / 578 | 100% | 13.28 | 1154 / 1155 |
ovary | 100% | 822.83 | 180 / 180 | 99% | 9.93 | 424 / 430 |
stomach | 100% | 583.89 | 359 / 359 | 98% | 14.26 | 281 / 286 |
bladder | 100% | 845.95 | 21 / 21 | 98% | 12.03 | 493 / 504 |
uterus | 100% | 845.79 | 170 / 170 | 97% | 10.60 | 447 / 459 |
pancreas | 100% | 456.63 | 328 / 328 | 97% | 7.69 | 173 / 178 |
thymus | 100% | 1550.47 | 653 / 653 | 97% | 10.70 | 586 / 605 |
prostate | 100% | 658.04 | 245 / 245 | 97% | 8.94 | 486 / 502 |
kidney | 100% | 543.58 | 89 / 89 | 94% | 7.21 | 844 / 901 |
skin | 100% | 1037.11 | 1809 / 1809 | 94% | 12.79 | 442 / 472 |
adrenal gland | 100% | 1002.94 | 258 / 258 | 89% | 7.09 | 204 / 230 |
liver | 100% | 393.65 | 225 / 226 | 79% | 5.34 | 320 / 406 |
adipose | 100% | 846.03 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 641.32 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.27 | 1 / 1 |
blood vessel | 100% | 652.66 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 897.09 | 801 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 10.66 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 11.08 | 28 / 29 |
heart | 96% | 642.94 | 826 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 71% | 5.96 | 57 / 80 |
peripheral blood | 55% | 482.76 | 512 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1900053 | Biological process | negative regulation of retinoic acid biosynthetic process |
GO_0019919 | Biological process | peptidyl-arginine methylation, to asymmetrical-dimethyl arginine |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0032259 | Biological process | methylation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0043022 | Molecular function | ribosome binding |
GO_0035241 | Molecular function | protein-arginine omega-N monomethyltransferase activity |
GO_0016274 | Molecular function | protein-arginine N-methyltransferase activity |
GO_0042054 | Molecular function | histone methyltransferase activity |
GO_0035242 | Molecular function | protein-arginine omega-N asymmetric methyltransferase activity |
GO_0008168 | Molecular function | methyltransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | PRMT3 |
Protein name | PRMT3 protein Protein arginine methyltransferase 3 Protein arginine N-methyltransferase 3 (EC 2.1.1.319) (Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3) |
Synonyms | HRMT1L3 |
Description | FUNCTION: Protein-arginine N-methyltransferase that catalyzes both the monomethylation and asymmetric dimethylation of the guanidino nitrogens of arginine residues in target proteins, and therefore falls into the group of type I methyltransferases (Probable). May regulate retinoic acid synthesis and signaling by inhibiting ALDH1A1 retinal dehydrogenase activity . . |
Accessions | ENST00000330796.9 ENST00000437750.2 [O60678-2] Q8WUV3 E9PRB4 E9PLF6 ENST00000525188.5 ENST00000526583.1 ENST00000331079.11 [O60678-1] O60678 |